Quanta Therapeutics
South San Francisco, US · 10 known investors
Find your way into Quanta Therapeutics
988 people in our graph share verified history with the Quanta Therapeutics team — schools, employers, funds. One of them is your warm intro.
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
Founders & leadership
Board
Investors · 10
Also in the syndicate · 5
Funding
SEC filings, press & company announcements$146.3M disclosed across 3 of 4 rounds · 2021–2023
- Undisclosed amountSeries DMay 2023 · 3 sources
Avidity Partners (lead), AbbVie Ventures, BVF Partners, GC&H Investments (the partner fund of Cooley LLP), Longitude Capital, Sofinnova Investments, Surveyor Capital (a Citadel company), Vida Ventures, WS Investment Company (Wilson Sonsini’s venture arm)
Source ↗
▶$76.2MraisedJun 2026 · 17 investors · BiotechnologyRule 506(b)
- Maha KatabiDirector
- Perry NisenExecutive Officer, Director
- Cameron PittExecutive Officer, Director
- Maria FardisDirector
- Ying HuangDirector
- Derek MetzgerExecutive Officer
- Rajul JainDirector
- Offering amount
- $89.1M
- Amount sold
- $76.2M
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedFeb 2023 · 9 investors · BiotechnologyRule 506(b)
- Arjun GoyalDirector
- Cameron PittExecutive Officer, Director
- Ying HuangDirector
- Perry NisenExecutive Officer, Director
- Samuel SaksDirector
- Leonardo FaoroExecutive Officer
- Maria FardisDirector
- Maha KatabiDirector
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$40.2MraisedNov 2021 · 10 investors · BiotechnologyRule 506(b)
- Cameron PittDirector
- Maha KatabiDirector
- Perry NisenExecutive Officer, Director
- Maria FardisDirector
- Samuel SaksDirector
- Arjun GoyalDirector
- Offering amount
- $70.2M
- Amount sold
- $40.2M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Quanta Therapeutics went on to found or lead other companies.
Competitors · 3
by search overlapCompanies competing with Quanta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Quanta Therapeutics do?
- Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers. Its pipeline includes clinical and preclinical candidates aimed at KRAS mutations (including G12D and G12V) beyond those addressed by approved G12C inhibitors, alongside a RAS-partner discovery program using conformation-sensitive assays.
- Who are Quanta Therapeutics's investors?
- Quanta Therapeutics's investors include Longitude Capital, Sofinnova Ventures, Vida Ventures, Biotechnology Value Fund, Frazier Life Sciences.
- How much funding has Quanta Therapeutics raised?
- Quanta Therapeutics has disclosed $146.3M raised across 3 of its 4 known rounds.
- Where is Quanta Therapeutics headquartered?
- Quanta Therapeutics is headquartered in South San Francisco, US.